Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel. more
Time Frame | PHGE | Sector | S&P500 |
---|---|---|---|
1-Week Return | -9.58% | -3.35% | -2.97% |
1-Month Return | -1.76% | -3.49% | -0.66% |
3-Month Return | -46.03% | -12.6% | 2.71% |
6-Month Return | -82.8% | -6.91% | 7.21% |
1-Year Return | -80.02% | 1.19% | 23.04% |
3-Year Return | -96.13% | -0.21% | 28.43% |
5-Year Return | -99.43% | 33.09% | 82.88% |
10-Year Return | -99.41% | 93.55% | 184.63% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | (134.00K) | (357.00K) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Cost of Revenue | 404.52K | 2.18M | 2.56M | 2.52M | 871.00K | [{"date":"2019-12-31","value":15.77,"profit":true},{"date":"2020-12-31","value":84.99,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.25,"profit":true},{"date":"2023-12-31","value":33.96,"profit":true}] |
Gross Profit | (404.52K) | (2.18M) | (2.56M) | (2.65M) | (1.23M) | [{"date":"2019-12-31","value":-40452100,"profit":false},{"date":"2020-12-31","value":-218000000,"profit":false},{"date":"2021-12-31","value":-256500000,"profit":false},{"date":"2022-12-31","value":-265400000,"profit":false},{"date":"2023-12-31","value":-122800000,"profit":false}] |
Gross Margin | - | - | - | 1980.60% | 343.98% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":17.37,"profit":true}] |
Operating Expenses | 22.21M | 30.26M | 35.46M | 27.22M | 26.81M | [{"date":"2019-12-31","value":62.62,"profit":true},{"date":"2020-12-31","value":85.33,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":76.76,"profit":true},{"date":"2023-12-31","value":75.61,"profit":true}] |
Operating Income | (22.21M) | (30.26M) | 35.46M | (27.22M) | (27.68M) | [{"date":"2019-12-31","value":-62.62,"profit":false},{"date":"2020-12-31","value":-85.33,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-76.76,"profit":false},{"date":"2023-12-31","value":-78.07,"profit":false}] |
Total Non-Operating Income/Expense | 2.81M | 1.37M | (1.32M) | (1.23M) | (131.00K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":48.77,"profit":true},{"date":"2021-12-31","value":-46.95,"profit":false},{"date":"2022-12-31","value":-43.78,"profit":false},{"date":"2023-12-31","value":-4.67,"profit":false}] |
Pre-Tax Income | (20.56M) | (30.09M) | (36.16M) | (28.25M) | (26.15M) | [{"date":"2019-12-31","value":-2056300000,"profit":false},{"date":"2020-12-31","value":-3008600000,"profit":false},{"date":"2021-12-31","value":-3615900000,"profit":false},{"date":"2022-12-31","value":-2825200000,"profit":false},{"date":"2023-12-31","value":-2614600000,"profit":false}] |
Income Taxes | (1.64M) | (172.00K) | 67.00K | 65.00K | 23.00K | [{"date":"2019-12-31","value":-2453.73,"profit":false},{"date":"2020-12-31","value":-256.72,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.01,"profit":true},{"date":"2023-12-31","value":34.33,"profit":true}] |
Income After Taxes | (18.92M) | (29.91M) | (36.23M) | (28.32M) | (26.17M) | [{"date":"2019-12-31","value":-1891900000,"profit":false},{"date":"2020-12-31","value":-2991400000,"profit":false},{"date":"2021-12-31","value":-3622600000,"profit":false},{"date":"2022-12-31","value":-2831700000,"profit":false},{"date":"2023-12-31","value":-2616900000,"profit":false}] |
Income From Continuous Operations | (20.56M) | (30.09M) | (36.23M) | (28.32M) | (26.56M) | [{"date":"2019-12-31","value":-2056300000,"profit":false},{"date":"2020-12-31","value":-3008600000,"profit":false},{"date":"2021-12-31","value":-3622600000,"profit":false},{"date":"2022-12-31","value":-2831700000,"profit":false},{"date":"2023-12-31","value":-2656400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (18.92M) | (29.91M) | (36.23M) | (28.32M) | (26.17M) | [{"date":"2019-12-31","value":-1891900000,"profit":false},{"date":"2020-12-31","value":-2991400000,"profit":false},{"date":"2021-12-31","value":-3622600000,"profit":false},{"date":"2022-12-31","value":-2831700000,"profit":false},{"date":"2023-12-31","value":-2616900000,"profit":false}] |
EPS (Diluted) | (0.38) | (1.26) | (1.38) | (0.95) | (1.01) | [{"date":"2019-12-31","value":-38,"profit":false},{"date":"2020-12-31","value":-126.5,"profit":false},{"date":"2021-12-31","value":-137.5,"profit":false},{"date":"2022-12-31","value":-95,"profit":false},{"date":"2023-12-31","value":-101,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
PHGE | |
---|---|
Cash Ratio | 2.76 |
Current Ratio | 3.17 |
Quick Ratio | 3.29 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
PHGE | |
---|---|
ROA (LTM) | -32.65% |
ROE (LTM) | -121.29% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
PHGE | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.37 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.63 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
PHGE | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.58 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.25 |
Biomx Inc (PHGE) share price today is $0.5694
Yes, Indians can buy shares of Biomx Inc (PHGE) on Vested. To buy Biomx Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PHGE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Biomx Inc (PHGE) via the Vested app. You can start investing in Biomx Inc (PHGE) with a minimum investment of $1.
You can invest in shares of Biomx Inc (PHGE) via Vested in three simple steps:
The 52-week high price of Biomx Inc (PHGE) is $8.55. The 52-week low price of Biomx Inc (PHGE) is $0.48.
The price-to-earnings (P/E) ratio of Biomx Inc (PHGE) is
The price-to-book (P/B) ratio of Biomx Inc (PHGE) is 0.58
The dividend yield of Biomx Inc (PHGE) is 0.00%
The market capitalization of Biomx Inc (PHGE) is $11.09M
The stock symbol (or ticker) of Biomx Inc is PHGE